Temasek ups India play with $151m Glenmark deal
This article was originally published in Scrip
Singapore government investment arm Temasek is pumping in about INR9.45bn ($151.6m) for about 3.8% in Glenmark Pharmaceuticals – funds that the Indian firm expects to use to retire debt.
You may also be interested in...
India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.